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Abstract
Background—Understanding the joint effects of insurance type and primary care physician 
density on stage at diagnosis is essential to elucidating the healthcare access and late-stage cancer 
relationship.
Purpose—To determine if the relationship between primary care physician density and odds of 
late-stage cancer is modified by insurance type at diagnosis.
Methods—Case patients were Ohio adults, diagnosed between 1996 and 2008 with cancer of one 
of the following sites: the female breast, cervix, colon/rectum, lung/bronchus, melanoma of the 
skin, oral cavity and pharynx, or prostate (N=376,425). County-level physician density was from 
Ohio Department of Health. Multilevel logistic regression models estimated odds ratios of 
latestage cancer diagnosis associated with increases in primary care physician density by 
insurance type. Analyses were conducted in 2014.
Results—Decreases in late-stage diagnosis of cancers of the breast, prostate, melanoma of the 
skin, oral cavity and pharynx, or lung/bronchus associated with increases in primary care 
physician density were strongest among those with private insurance, whereas those with 
Medicare (prostate, oral cavity and pharynx, lung/bronchus), Medicaid (lung/bronchus), uninsured 
(prostate), and other/unknown (prostate, oral cavity and pharynx, lung/bronchus) did not benefit as 
greatly or experienced significant increases in late-stage cancer diagnosis (other/unknown [female 
breast], Medicaid [melanoma of the skin], and uninsured [colon/rectum]).
Conclusions—As primary care physician density increases, those with private insurance 
consistently benefit the most, in terms of late-stage cancer diagnosis, whereas those with several 
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other insurance types experience flatter decreases or significantly higher odds of late-stage cancer 
diagnosis.
Introduction
Cancer stage at diagnosis is an important survival indicator.1 Identifying factors related to 
late-stage cancer diagnosis is important for reducing mortality. Several biological, 
demographic, social, and environmental factors are related to cancer stage at diagnosis.2–6 
SES and measures of healthcare access (e.g., insurance coverage, primary care physician 
[PCP] density—the number of PCPs per residents) are social and environmental factors 
associated with late-stage cancer diagnosis.2,4,7–10
PCP density is inversely associated with late-stage breast cancer,3,9,11,12 but associations 
with other cancers are unclear.13–15 The relationship between PCP use and uptake of cancer 
screening tests is well-studied; however, less is known about mechanisms governing the 
relationship between PCP density and late-stage cancer diagnoses.16–18 It is possible that the 
association results from increased opportunity for early-stage detection.3,19
Insurance type at diagnosis is an important predictor of late-stage cancer diagnosis.2,6,8,10 
Compared to those with private insurance, those lacking any health insurance or with 
Medicaid have double the odds of late-stage diagnoses of cancers of the breast, colon/
rectum, lung/bronchus, urinary bladder, and melanoma of the skin.8,10 A high proportion of 
several cancers for which screening is not recommended are diagnosed at early-stage, 
indicating that these cancers are not found through recommended screening procedures.1
It is not reasonable to assume that all health insurance groups experience equal reductions in 
late-stage cancer diagnosis with increased PCP density. Those who rarely see physicians 
because of inadequate insurance may not benefit from living in areas with high PCP density. 
The purpose of this study is to investigate the dependent effects of insurance type and PCP 
density on odds of late-stage cancer diagnosis across cancer sites. The authors hypothesize 
that reductions in late-stage cancer diagnosis associated with increases in PCP density are 
greatest for those with private insurance.
Methods
Data Description
Data were from the Ohio Cancer Incidence Surveillance System (OCISS).20 Malignancies 
were coded according to the International Classification of Diseases for Oncology, Third 
Edition (ICD-O-3), codes C00.0-C80.9.2122 Invasive cancers with potential to be detected 
early through screening were included: cervix, colon/rectum, female breast, lung/bronchus, 
melanoma of the skin, oral cavity and pharynx, and prostate. Case patients (N=456,821) 
were Ohio adults diagnosed between 1996 and 2008. These non-identifiable data qualified 
for IRB exemption status.
Stage at diagnosis was dichotomized as late (i.e., regional or distant) or early (i.e., localized) 
according to Surveillance Epidemiology and End Results summary staging.22 In situ tumors 
were excluded.6,8,12,15 Those with missing/unknown staging information were excluded 
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(n=56,763, 12.3%). Additional individual-level factors included insurance type, age, sex, 
race, diagnosis year, marital status, and county of residence. Those aged younger than 65 
years reporting Medicare were excluded (n=13,081, 2.8%). Those with Medicare but eligible 
for Medicaid were classified as Medicare (n=6,582, 1.5%). County-level factors were Rural–
Urban Continuum Code (RUCC—based on population size, degree of urbanization, and 
adjacency to metropolitan area)23; year 2007 PCP, total physician, and specialty physician 
densities (physician count per 100,000 population)24; and year 2000 percentage with at least 
a bachelor’s degree (hereafter, “county SES”).25 County physician data were limited to 
active, non-federal, non-pediatric physicians involved in patient care,24 and having a 
practice of family medicine/general practice, general internal medicine, or obstetrics and 
gynecology; specialty physicians excluded all others.
Statistical Analyses
ORs and 95% CIs comparing late- versus early-stage by the aforementioned factors were 
calculated. Cancer site-specific, hierarchical logistic regression models were used.26,27 
Interactions were multiplicative. Age, diagnosis year, and county-level factors were modeled 
as continuous variables. Linearity of the PCP–late-stage cancer relationship was assessed 
visually using scatter plots. Type-I error was held at 0.05. Analyses were conducted in 2014 
using SAS, version 9.2 (SAS Institute Inc., Cary NC).
Results
Of 376,425 (54.5% early-stage, 45.5% late-stage) invasive cancer diagnoses, 44.1% were 
insured through Medicare, 21.0% with private insurance, 27.5% with unknown (13.9%)/
other (13.6%), 3.9% uninsured, and 3.5% with Medicaid. After adjustment for age, race, 
sex, year, marital status, county SES, RUCC, and PCP rate (hereafter, “other factors”), 
insurance type was significantly related to late-stage diagnosis across cancer sites, while the 
only county-level factor significantly associated with late-stage diagnosis was SES among 
those with melanoma of the skin (Table 1).
After adjustment for other factors, there was significant effect modification of the PCP 
density– late-stage cancer relationship in at least one insurance type (compared to private) 
for each cancer site except that of the cervix (Figure 1A–1F). Decreases in late-stage 
diagnosis of cancers of the breast, prostate, oral cavity and pharynx, or lung/bronchus 
associated with increases in PCP density were strongest among those with private insurance, 
whereas those with Medicare (prostate, oral cavity and pharynx, lung/bronchus), Medicaid 
(lung/bronchus), uninsured (prostate), and other/unknown (prostate, oral cavity and pharynx, 
lung/bronchus) did not benefit as greatly or experienced significant increases in late-stage 
cancer diagnosis (other/unknown [female breast], Medicaid [melanoma of the skin],and 
uninsured [colon/rectum]).
Discussion
This is the first known study to demonstrate significant effect modification between PCP 
density and insurance type on odds of late-stage cancer diagnosis. As PCP density increases, 
those with private insurance consistently benefit the most, in terms of late-stage cancer 
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diagnosis, whereas those with several other insurance types experience flatter decreases or 
significantly higher odds of late-stage cancer diagnosis.
Studies of the independent effects of PCP density have consistently demonstrated inverse 
association with late-stage breast9,11,12,28 and colorectal cancer diagnoses.14,29 Though no 
other study has tested effect modification of the PCP density–late-stage cancer relationship 
by insurance type, others have found that this relationship does not change when stratifying 
by fee-for-service insurance plans.3,19
Effect modification of the PCP density–late-stage cancer relationship by insurance type may 
result from differential healthcare access; those with private insurance may capitalize on 
greater PCP supply and utilize preventive services more frequently than those with other 
insurance types. This may not occur for cervical cancer because the screening test has high 
and widespread uptake.30
This study is limited by possible uncontrolled confounding by individual-level SES, 
comorbidities, and additional measures of healthcare accessibility (e.g., insurance 
acceptability). Insurance type does not capture out-of-pocket costs and duration of coverage. 
PCP data were available only at the county level,24 which may be too large an area in which 
to measure PCP density. Additionally, it was not possible to determine whether those with 
early-stage cancer diagnosis saw a PCP. Results may be limited by data quality—
approximately 12% of case patients were excluded owing to unknown stage and 13.6% had 
unknown insurance type. Case patients were from Ohio and may not represent other 
geographic regions, limiting generalizability. Strengths of this study include examination of 
two measures of healthcare access and consideration of several confounders within 
hierarchical statistical models.
Future investigations of late-stage cancer diagnoses should examine relationships between 
multiple measures of healthcare access. Insurance type is associated with late-stage cancer 
diagnoses across cancer sites. However, effects of PCP density on late-stage cancer 
diagnosis are more nuanced. The possibility that increases in PCP density may contribute to 
sharper reductions in late-stage cancer diagnosis among those with private insurance 
compared to other insurance types necessitates that more detailed attention be given to PCP 
density and health insurance type. Targeting of healthcare resources in higher–PCP density 
areas may ensure reductions of late-stage cancer diagnosis equally across all health 
insurance types.
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Insurance type-specific, late-stage cancer diagnosis odds ratios associated with increases in 
PCP densitya,b
a Odds ratios are for a change in the interquartile range (23.0 per 100,000) of PCP density
b Adjusted for age, race, sex, year, marital status, Rural Urban Continuum Code and percent 
of residents with at least a bachelor’s degree
* P < 0.05 for test of stratum-specific interaction with private as reference
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